Hi professor

This is Ritu Adhikari from NUR 409, and I have chosen to do paper on a new drug Symdeko (tezacaftor/vacaftor) that was approved by FDA in 2018. Symdeko is given to treat patient with cystic fibrosis. I will be using the following reference for my paper.

**Reference**

FDA Approves SYMDEKOTM (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene. (2018, February 13). *The New York times*. Retrieved March 11, 2018, from

<http://markets.on.nytimes.com/research/stocks/news/press_release.asp>?

[SYMDEKO (tezacaftor/ivacaftor) tablets](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf)

**(2018-02-13)**. Retrieved March 11,2018, from

<https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf>

##### **Vertex Secures Us Approval for SYMDEKO.** Selina McKee. (2018, February 13). Pharma Times. Retrieved March 11, 2018, from

<http://www.pharmatimes.com/news/vertex_secures_us_approval_for_symdeko_1221731>